UB Paderborn / Katalog / Suche / in CDI

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3764-3773

2016

Link zum Volltext

Verfügbarkeit prüfen

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Journal of clinical oncology, 2020-06, Vol.38 (18), p.2080-2106

2020

Link zum Volltext

Verfügbarkeit prüfen

Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis

Breast cancer research : BCR, 2019-09, Vol.21 (1), p.107-107, Article 107

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1145-1153

2010

Link zum Volltext

Verfügbarkeit prüfen

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer

Journal of clinical oncology, 2015-03, Vol.33 (9), p.969-971

2015

Link zum Volltext

Verfügbarkeit prüfen

Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors

Journal of clinical oncology, 2004-12, Vol.22 (24), p.4951-4957

2004

Link zum Volltext

Verfügbarkeit prüfen

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

British journal of cancer, 2019-07, Vol.121 (1), p.15-21

2019

Link zum Volltext

Verfügbarkeit prüfen

Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers

Cancer research (Chicago, Ill.), 2009-02, Vol.69 (4), p.1273-1278

2009

Link zum Volltext

Verfügbarkeit prüfen

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Journal of clinical oncology, 2019-09, Vol.37 (25), p.2189-2192

2019

Link zum Volltext

Verfügbarkeit prüfen

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2720-2731

2021

Link zum Volltext

Verfügbarkeit prüfen

How to manage patients with moderate-risk germline mutations

Clinical advances in hematology & oncology, 2018-02, Vol.16 (2), p.97

Tung, Nadine M

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Clinical cancer research, 2022-11, Vol.28 (21), p.4714-4723

2022

Link zum Volltext

Verfügbarkeit prüfen

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma

JNCI : Journal of the National Cancer Institute, 2017-10, Vol.109 (10)

2017

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

The oncologist (Dayton, Ohio), 2023-07, Vol.28 (7), p.565-574

2023

Link zum Volltext

Verfügbarkeit prüfen

Variation in Breast Cancer Risk Model Estimates Among Women in Their 40s Seen in Primary Care

Journal of women's health (Larchmont, N.Y. 2002), 2022-04, Vol.31 (4), p.495

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.641-651

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial

Journal of the American College of Surgeons, 2023-08, Vol.237 (2), p.247-256

2023

Link zum Volltext

Verfügbarkeit prüfen

The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

Cancer, 2023-03, Vol.129 (6), p.901-907

2023

Link zum Volltext

Verfügbarkeit prüfen

Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Annals of internal medicine, 2016-08, Vol.165 (3), p.194

2016

Link zum Volltext

Verfügbarkeit prüfen

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

Annals of surgical oncology, 2019-02, Vol.26 (2), p.366-371

2019

Link zum Volltext

Verfügbarkeit prüfen

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

Annals of surgical oncology, 2014-08, Vol.21 (8), p.2506-2511

2014

Link zum Volltext

Verfügbarkeit prüfen

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Future oncology (London, England), 2021-12, Vol.17 (34), p.4665-4676

2021

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel

Breast cancer research and treatment, 2015-09, Vol.153 (2), p.455-464

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer

Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

How to manage patients with moderate-risk germline mutations

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

Variation in Breast Cancer Risk Model Estimates Among Women in Their 40s Seen in Primary Care

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial

The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab

Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel

Aktive Filter

Suchergebnisse filtern